Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the efficacy of fluticasone propionate
(Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS)
MDPI when administered over 12 weeks in patients 12 years of age and older with persistent
asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.